• Publications
  • Influence
Combined Salmeterol 50 μ g and Fluticasone Propionate 250 μ g in the Diskus Device for the Treatment of Asthma
Patients in the combination-product group had a significantly greater probability of remaining in the study without being withdrawn because of worsening asthma than did patients in the placebo, salmeterol, or FP groups. Expand
Mediators of inflammation and the inflammatory process.
  • M. White
  • Medicine
  • The Journal of allergy and clinical immunology
  • 1 March 1999
A summary of the early- and late-phase events associated with allergic inflammation and an overview of the principal chemical mediators involved in the inflammatory process are provided. Expand
Estimation of nasal epithelial lining fluid using urea as a marker.
Data indicate the plasma, interstitial, glandular, and ELF urea concentrations are equivalent and, therefore, that urea is a useful marker of ELF volume in the nasal mucosa. Expand
EpiPen4Schools pilot survey: Occurrence of anaphylaxis, triggers, and epinephrine administration in a U.S. school setting.
Analysis of anaphylactic events and epinephrine autoinjector (EAI) use in U.S. schools enrolled in the EpiPen4Schools program during the 2013-2014 school year supports the value of stocking EAIs and of providing continuing education regarding the recognition and proper treatment ofAnaphylaxis for school personnel. Expand
Asthma exacerbations in African Americans treated for 1 year with combination fluticasone propionate and salmeterol or fluticasone propionate alone
The addition of salmeterol to FP resulted in a similar low rate of exacerbations and improved other markers of asthma control, and it remains unknown whether this intervention may affect generalizability. Expand
Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma.
Combination treatment with salmeterol 50 microg and FP 250 microg given twice daily from the Diskus device provided better asthma control and greater improvement in pulmonary function than did the individual agents, and may simplify the management of asthma in patients who need both classes of drugs for optimal control of their disease. Expand
Psychometric validation of two patient-reported outcome measures to assess symptom severity and changes in symptoms in hereditary angioedema
PurposeHereditary angioedema (HAE) is a rare disorder characterized by highly variable, acute attacks of swelling at various anatomical locations. Clinical measures do not adequately assess theExpand
Efficacy and Safety of Fluticasone Propionate/Salmeterol HFA 134A MDI in Patients with Mild‐to‐Moderate Persistent Asthma
Treatment with FSC resulted in significantly greater improvements in morning and evening peak expiratory flow, need for rescue albuterol, and asthma symptom scores compared with FP, S, and PLA. Expand
Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine.
  • W. Berger, M. White
  • Medicine
  • Annals of allergy, asthma & immunology : official…
  • 1 August 2003
Azelastine nasal spray is an effective treatment for patients with seasonal allergic rhinitis who do not respond to loratadine and is an alternative to switching to another oral antihistamine or to using multiple antihistamines. Expand
Distribution of secretory leukoprotease inhibitor in the human nasal airway.
The distribution ofSLPI in the human nasal mucosa was determined and the functional activity of SLPI in nasal lavage fluid was quantitated, revealing intense, selective immunoreactivity in the serous cells of the submucosal glands. Expand